Neuphoria Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Neuphoria Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Neuphoria Therapeutics Inc.
Rating: 1.94558325
Author: Trendlyne DVM scores

about

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral...

5.04 0.13 (2.65%)

76.45% Fall from 52W High

30,105

XNAS Volume

XNAS 24 Apr, 2026 5:30 PM (EDT)

Not Eligible

Expensive Valuation

27.8 / 100

Technically Neutral

50.0 / 100

1Yr Price target upside is 168%

2 analysts

Neuphoria Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Neuphoria Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral...

76.45% Fall from 52W High

SWOT Analysis

Neuphoria Therapeutics Inc Live Price Chart